Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase
Proceedings of the National Academy of Sciences · 21.05.2024 · 121 (21)
DOI: 10.1073/pnas.2403685121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.05.2024. Verfasst von John R Ferrarone und 14 weiteren Autor:innen. Beteiligte Einrichtung: Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, AMP-Activated Protein Kinase Kinases, Spheroids, Cellular, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | NCI | CCR | Basic Research Laboratory (BRL), Damon Runyon Cancer Research Foundation (DRCRF), NCI NIH HHS.
Abstract (Originalsprache)
The tumor suppressor LKB1 is a serine/threonine protein kinase that is frequently mutated in human lung adenocarcinoma (LUAD). LKB1 regulates a complex signaling network that is known to control cell polarity and metabolism; however, the pathways that mediate the tumor-suppressive activity of LKB1 are incompletely defined. To identify mechanisms of LKB1-mediated growth suppression, we developed a spheroid-based cell culture assay to study LKB1-dependent growth. We then performed genome-wide CRISPR screens in spheroidal culture and found that LKB1 suppresses growth, in part, by activating the PIKFYVE lipid kinase. Finally, we used chemical inhibitors and a pH-sensitive reporter to determine that LKB1 impairs growth by promoting the internalization of wild-type EGFR in a PIKFYVE-dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021.
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY 10021.
- Department of Pharmacology, Weill Cornell Medicine, New York, NY 10021.
- New York Genome Center, New York, NY 10013.
- Department of Biology, New York University, New York, NY 10003.
- Department of Medicine, Weill Cornell Medicine, New York, NY 10021.
ORCID-Profile: John R Ferrarone, Lewis C Cantley, John Blenis, Neville E Sanjana, Harold Varmus
Förderung
- HHS | NIH | NCI | CCR | Basic Research Laboratory (BRL)
- Damon Runyon Cancer Research Foundation (DRCRF)
- NCI NIH HHS
- NHGRI NIH HHS
- HHS | NIH | National Human Genome Research Institute (NHGRI)
Zitieren
APA
Ferrarone, J. R., Thomas, J., Unni, A. M., Zheng, Y., Nagiec, M. J., Gardner, E. E., Mashadova, O., Li, K., Koundouros, N., Montalbano, A., Mustafa, M., Cantley, L. C., Blenis, J., Sanjana, N. E., & Varmus, H. (2024). Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. Proceedings of the National Academy of Sciences, 121(21). https://doi.org/10.1073/pnas.2403685121
Vancouver
Ferrarone JR, Thomas J, Unni AM, Zheng Y, Nagiec MJ, Gardner EE, et al. Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. Proceedings of the National Academy of Sciences. 2024;121(21). doi:10.1073/pnas.2403685121
BibTeX
@article{Ferrarone2024,
author = {Ferrarone, John R and Thomas, Jerin and Unni, Arun M and Zheng, Yuxiang and Nagiec, Michal J and Gardner, Eric E and Mashadova, Oksana and Li, Kate and Koundouros, Nikos and Montalbano, Antonino and Mustafa, Meer and Cantley, Lewis C and Blenis, John and Sanjana, Neville E and Varmus, Harold},
title = {Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {21},
doi = {10.1073/pnas.2403685121}
}
EUVIMED